Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria
In about 20%-30% of phenylketonuria (PKU) patients (all phenotypes of PAH deficiency), Phe levels may be controlled through phenylalanine hydroxylase cofactor tetrahydrobiopterin therapy. These patients can be diagnosed by an oral tetrahydrobiopterin challenge and are characterized by mutations codi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
04 April 2013
|
| In: |
Human mutation
Year: 2013, Volume: 34, Issue: 7, Pages: 927-936 |
| ISSN: | 1098-1004 |
| DOI: | https://doi.org/10.1002/humu.22320 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/https://doi.org/10.1002/humu.22320 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/humu.22320 
|
| Author Notes: | Caroline Heintz, Richard G. H. Cotton, and Nenad Blau |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1752685946 | ||
| 003 | DE-627 | ||
| 005 | 20230427070830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210329s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/humu.22320 |2 doi | |
| 035 | |a (DE-627)1752685946 | ||
| 035 | |a (DE-599)KXP1752685946 | ||
| 035 | |a (OCoLC)1341401696 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Heintz, Caroline |e VerfasserIn |0 (DE-588)1156470110 |0 (DE-627)1019289589 |0 (DE-576)502200111 |4 aut | |
| 245 | 1 | 0 | |a Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria |c Caroline Heintz, Richard G. H. Cotton, and Nenad Blau |
| 264 | 1 | |c 04 April 2013 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.03.2021 | ||
| 520 | |a In about 20%-30% of phenylketonuria (PKU) patients (all phenotypes of PAH deficiency), Phe levels may be controlled through phenylalanine hydroxylase cofactor tetrahydrobiopterin therapy. These patients can be diagnosed by an oral tetrahydrobiopterin challenge and are characterized by mutations coding for proteins with substantial residual PAH activity. They can be treated with a commercially available synthetic form of tetrahydrobiopterin, either as a monotherapy or as adjunct to the diet. This review article summarizes molecular and metabolic bases of PKU and the importance of the tetrahydrobiopterin loading test used for PKU patients. On the basis of in vitro residual PAH activity, more than 1,200 genotypes from patients challenged with tetrahydrobiopterin were categorized as predictive for tetrahydrobiopterin responsiveness or non-responsiveness and correlated with the loading test, phenotype, and residual in vitro PAH activity. The coexpression of two distinct PAH mutant alleles revealed possible dominance effects (positive or negative) by one of the mutations on residual activity as result of interallelic complementation. The treatment of the transfected cells with tetrahydrobiopterin showed an increase in residual PAH activity with several mutations coexpressed. | ||
| 650 | 4 | |a BH4 | |
| 650 | 4 | |a chaperones | |
| 650 | 4 | |a hyperphenylalaninemia | |
| 650 | 4 | |a PKU | |
| 650 | 4 | |a sapropterin | |
| 700 | 1 | |a Cotton, Richard G. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blau, Nenad |d 1946- |e VerfasserIn |0 (DE-588)11474632X |0 (DE-627)500421803 |0 (DE-576)176516107 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human mutation |d [Hoboken, NJ] : Wiley, 1992 |g 34(2013), 7, Seite 927-936 |h Online-Ressource |w (DE-627)306586193 |w (DE-600)1498165-8 |w (DE-576)250043572 |x 1098-1004 |7 nnas |a Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria |
| 773 | 1 | 8 | |g volume:34 |g year:2013 |g number:7 |g pages:927-936 |g extent:10 |a Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria |
| 856 | 4 | 0 | |u https://doi.org/https://doi.org/10.1002/humu.22320 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/humu.22320 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210329 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 11474632X |a Blau, Nenad |m 11474632X:Blau, Nenad |d 910000 |d 910500 |e 910000PB11474632X |e 910500PB11474632X |k 0/910000/ |k 1/910000/910500/ |p 3 |y j | ||
| 999 | |a KXP-PPN1752685946 |e 3896773526 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 29.03.2021"],"recId":"1752685946","type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria","title_sort":"Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria"}],"id":{"doi":["10.1002/humu.22320"],"eki":["1752685946"]},"name":{"displayForm":["Caroline Heintz, Richard G. H. Cotton, and Nenad Blau"]},"physDesc":[{"extent":"10 S."}],"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"04 April 2013"}],"relHost":[{"id":{"eki":["306586193"],"zdb":["1498165-8"],"doi":["10.1002/(ISSN)1098-1004"],"issn":["1098-1004"]},"recId":"306586193","part":{"text":"34(2013), 7, Seite 927-936","extent":"10","year":"2013","pages":"927-936","volume":"34","issue":"7"},"note":["Gesehen am 27.01.2025"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1992 -"],"title":[{"title_sort":"Human mutation","title":"Human mutation"}],"disp":"Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuriaHuman mutation","language":["eng"],"origin":[{"publisherPlace":"[Hoboken, NJ] ; New York, NY [u.a.] ; London","dateIssuedKey":"2024","dateIssuedDisp":"2024-","publisher":"Wiley ; Wiley-Liss ; Hindawi Limited"}],"physDesc":[{"extent":"Online-Ressource"}]}],"person":[{"family":"Heintz","display":"Heintz, Caroline","given":"Caroline","role":"aut","roleDisplay":"VerfasserIn"},{"family":"Cotton","roleDisplay":"VerfasserIn","role":"aut","given":"Richard G. H.","display":"Cotton, Richard G. H."},{"given":"Nenad","roleDisplay":"VerfasserIn","role":"aut","display":"Blau, Nenad","family":"Blau"}],"language":["eng"]} | ||
| SRT | |a HEINTZCAROTETRAHYDRO0420 | ||